UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000018734
Receipt No. R000021671
Scientific Title Japan colorectal tumor prevention study: clinical trial by low-dose aspirin
Date of disclosure of the study information 2015/08/21
Last modified on 2016/08/20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Japan colorectal tumor prevention study: clinical trial by low-dose aspirin
Acronym Japan colorectal tumor prevention study: clinical trial by low-dose aspirin (J-CAPP Study 2)
Scientific Title Japan colorectal tumor prevention study: clinical trial by low-dose aspirin
Scientific Title:Acronym Japan colorectal tumor prevention study: clinical trial by low-dose aspirin (J-CAPP Study 2)
Region
Japan

Condition
Condition Patients with colorectal tumor (adenoma, carcinoma in situ)
Classification by specialty
Gastroenterology
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 he objective of this study is to evaluate the colorectal cancer preventive effect of aspirin enteric-coated tablet (100 mg, one tablet daily) in a single arm study.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2 Pragmatic
Developmental phase Phase III

Assessment
Primary outcomes The primary endpoint is set as the incidence of newly diagnosed colorectal Index Lesion (adenomas >= 10 mm in diameter, adenomas with high-grade dysplasia, or invasive cancer) during 4 years observation excluding the first year observation.
Key secondary outcomes The secondary endpoints included i) the frequency of adverse effects, development of cancers in other organs, the occurrence of newly diagnosed colorectal tumors (adenoma and adenocarcinoma) at the first year colon endoscopy, ii) the number, size and histology (examination of a grade of atypism and existence of a villus-like colon adenoma) of the colorectal tumors that detected at the first and 4th year colon endoscopy, and iii) the occurrence of newly diagnosed colorectal tumors (adenoma and adenocarcinoma) at the 7th year colon endoscopy. Regarding diagnosis of borderline lesion, central review will be considered.

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Prevention
Type of intervention
Medicine
Interventions/Control_1 aspirin enteric-coated tablet (100 mg, one tablet daily) for four years
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit
69 years-old >=
Gender Male and Female
Key inclusion criteria Candidate patients have to meet all the following inclusion criteria to participate in
the study.
# Patients with at least one colorectal tumor (intramucosal cancer and adenoma) as confirmed by histological diagnosis, all of which have been removed endoscopically including the past.
# Patients with known history of all endoscopic treatments (including histological diagnosis) of colorectal tumors. Patients without histological diagnosis but have histological sections could participate in the trial.
# Patients who have undergone total colonoscopy at least twice.
# Patients with clean colon as confirmed by total colonoscopy within 3 months before the study. All histological diagnosis of the colorectal polyps should be done before the trial start.
Key exclusion criteria # Patients with a medical history of submucosal (sm) or deeper colorectal cancer.
# Patients with familial adenomatous polyposis or Lynch syndrome.
# Patients currently taking antithrombotics such as Bayaspirin, Panaldine, Warfarin and Persantin etc.
# Patients with known allergy to aspirin.
# Patients who have undergone colorectal resection (those who have undergone appendectomy are allowed to participate in the study).
# Women who are or may be pregnant during the study period.
# Patients with a history of treatment of gastric or duodenal ulcer (those with successful eradication of Helicobacter pylori and ulcer resolution at S2 are allowed to participate in the study)
# Patients with inflammatory bowel disease (ulcerative colitis, Crohn syndrome), bleeding diverticulosis, bleeding gastritis.
# Patients with bleeding tendency, a platelet count of < 100,000 /mm3, or with abnormal prothrombin time.
# Patients with any existing cancer at the time of participation in the study.
# Patients currently taking anticancer drugs.
# Patients currently taking NSAIDs at least 3 times weekly, for example, as a analgesic.
Target sample size 7000

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Hideki Ishikawa
Organization Kyoto Prefectural University of Medicine
Division name Department of Molecular-Targeting Cancer Prevention
Zip code
Address 3-2-17-2F Imabashi, Chuo-ku, Osaka 541-0042, Japan
TEL 06-6202-5444
Email cancer@gol.com

Public contact
Name of contact person
1st name
Middle name
Last name Hideki Ishikawa
Organization Kyoto Prefectural University of Medicine
Division name Department of Molecular-Targeting Cancer Prevention
Zip code
Address 3-2-17-2F Imabashi, Chuo-ku, Osaka 541-0042, Japan
TEL 06-6202-5444
Homepage URL
Email cancer@gol.com

Sponsor
Institute Kyoto Prefectural University of Medicine
Institute
Department

Funding Source
Organization Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions NTT東日本札幌病院(北海道)、斗南病院(北海道)、秋田赤十字病院(秋田県)、国立がん研究センター中央病院(東京都)、東京慈恵会医科大学(東京都)、国立がん研究センター東病院(千葉県)、東邦大学医療センター大橋病院(千葉県)愛知がんセンター中央病院(愛知県)、静岡県立静岡がんセンター(静岡県)、石川県立中央病院(石川県)、金沢医科大学(石川県)、京都桂病院(京都府)、石川消化器内科(大阪府)、近畿大学(大阪府)、北摂総合病院(大阪府)、大阪府立成人病センター(大阪府)、宝塚市立病院(兵庫県)、佐野病院(兵庫県)、広島大学(広島県)、広島市立安佐市民病院(広島県)、四国がんセンター(愛媛県)、尾田胃腸内科(熊本県)

Other administrative information
Date of disclosure of the study information
2015 Year 08 Month 21 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2015 Year 07 Month 22 Day
Date of IRB
Anticipated trial start date
2015 Year 09 Month 07 Day
Last follow-up date
2024 Year 03 Month 31 Day
Date of closure to data entry
2024 Year 08 Month 31 Day
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2015 Year 08 Month 20 Day
Last modified on
2016 Year 08 Month 20 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021671

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.